Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead Sciences : Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 11:07am CEST

Release date- 05102017 - FOSTER CITY, Calif. - Gilead Sciences, Inc.(NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone.

In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. The data are being presented at IDWeek 2017 in San Diego (Session 228).

'These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs,' said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. 'The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-naive patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.'

In Study 1878, a total of 577 virologically suppressed adults with HIV taking regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their bPI regimen or to switch to open-label coformulated BIC/FTC/TAF once daily. At the primary endpoint of Week 48, switching to BIC/FTC/TAF was non-inferior to continuing on a bPI regimen with 1.7 percent of patients in each group having HIV-1 RNA 50 c/mL (difference: 0.0 percent, 95 percent CI: -2.5 percent to 2.5 percent, p=1.00); the proportion of patients with HIV-1 RNA

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10:13aGILEAD SCIENCES : Biker nun on a mission to free Tanzania from grip of HIV
AQ
07/21GILEAD SCIENCES : Gadeta Forms Strategic Collaboration With Kite to Advance Gamm..
AQ
07/21GILEAD SCIENCES : Gov. Scott's policies helping investments in Gilead
AQ
07/20GILEAD SCIENCES, INC. : half-yearly earnings release
07/20GILEAD SCIENCES : Michael Amoroso to Join Kite as Senior Vice President and Head..
AQ
07/19GILEAD SCIENCES : Receives Approval in Canada for BIKTARVY™ bictegravir, e..
AQ
07/19GILEAD SCIENCES : Kite and Gadeta Announce Strategic Collaboration to Advance Ga..
BU
07/18GILEAD SCIENCES : Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment..
AQ
07/17GILEAD SCIENCES : to Release Second Quarter 2018 Financial Results on Wednesday,..
AQ
07/13GILEAD SCIENCES : to Release Second Quarter 2018 Financial Results on Wednesday,..
BU
More news
News from SeekingAlpha
07/21STOCKS TO WATCH : FANGs Out In Tech 
07/20QUARTERLY REVIEW OF DIVGRO : Q2 2018 
07/20MUSTANG BIO : A Differentiated CAR-T Innovator With Multiple Unlocking Catalysts 
07/19Liquidia Technologies Readies $50 Million IPO 
07/19Big Pharma in the red on ramped up pressure on drug prices 
Financials ($)
Sales 2018 20 806 M
EBIT 2018 10 735 M
Net income 2018 6 406 M
Debt 2018 12 164 M
Yield 2018 2,94%
P/E ratio 2018 15,69
P/E ratio 2019 14,31
EV / Sales 2018 5,40x
EV / Sales 2019 5,51x
Capitalization 100 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES8.00%100 185
VERTEX PHARMACEUTICALS18.38%45 900
REGENERON PHARMACEUTICALS-2.35%38 962
GENMAB9.33%10 874
NEUROCRINE BIOSCIENCES, INC.33.30%9 332
BLUEBIRD BIO INC1.26%8 969